Clinical trial

Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy…

NCT00046852 · University of Maryland, Baltimore, Other · Completed

Key facts

NCT number NCT00046852
Title Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma
Official title High-Dose Therapy and Autologous Blood Stem Cell Transplantation (ASCT) Followed by Post-Transplant Immunotherapy With Costimulated Autologous T-Cells in Conjunction With Pneumococcal Conjugate Vaccine Immunization for Patients With Multiple Myeloma
Lead sponsor University of Maryland, Baltimore, Other
Collaborators University of Maryland Greenebaum Cancer Center
Status Completed
Phase Phase 1/Phase 2
Study type Interventional
Conditions Infection, Multiple Myeloma and Plasma Cell Neoplasm
Intervention type Biological, Drug, Procedure
Interventions filgrastim, pneumococcal polyvalent vaccine, therapeutic autologous lymphocytes, therapeutic tumor infiltrating lymphocytes, carmustine, cyclophosphamide, melphalan, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Start date Dec 1, 2001
Primary completion Nov 1, 2004
Completion Feb 1, 2008
First posted Jan 27, 2003
Last update posted Nov 4, 2019
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies